Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prelude TherapeuticsPRLD -0.22%30 3-Year FCF Growth Rate is 26.30% as of Jun. 2026, which is 168% above its 10-year median of 9.80. GuruFocus rates PRLD with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,105 Biotechnology companies, Prelude Therapeutics ranks better than 59.28% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 26.30% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 22.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 8 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Prelude Therapeutics was 26.30% per year. The lowest was -64.30% per year. And the median was 9.80% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Prelude Therapeutics 3-Year FCF Growth Rate Related Terms
PRLD vs CMPX, ARCT, AVIR: 3-Year FCF Growth Rate Comparison
For the Biotechnology subindustry, Prelude Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prelude Therapeutics 3-Year FCF Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Prelude Therapeutics's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 26.30% mean?
Prelude Therapeutics (PRLD) has a 3-Year FCF Growth Rate of 26.30% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Prelude Therapeutics and its competitors. This is 168% above median its historical median of 9.80. According to the industry distribution chart, Prelude Therapeutics ranks #450 out of 1105 companies in the Biotechnology industry, placing it in the top 40.7%.
Is Prelude Therapeutics' 3-Year FCF Growth Rate too high?
Prelude Therapeutics' current 3-Year FCF Growth Rate of 26.30% is 168% above median its 10-year median of 9.80. The Biotechnology industry median 3-Year FCF Growth Rate is 19.30. Prelude Therapeutics' value of 26.30% is 36.3% above this industry median. Based on the distribution chart, Prelude Therapeutics ranks #450 out of 1105 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Prelude Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' 3-Year FCF Growth Rate compare to CMPX and ARCT?
According to the Biotechnology industry distribution chart, Prelude Therapeutics ranks #450 out of 1105 companies for 3-Year FCF Growth Rate. This puts Prelude Therapeutics in the upper half of its industry. The industry median 3-Year FCF Growth Rate is 19.30. Prelude Therapeutics' value of 26.30% is 36.3% above this benchmark. While the company's 10-year median is 9.80 vs. the industry median of 19.30, Prelude Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Biotechnology company?
The median 3-Year FCF Growth Rate among Biotechnology companies is 19.30, based on 1,105 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prelude Therapeutics's current 3-Year FCF Growth Rate of 26.30% is 36.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Prelude Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year FCF Growth Rate is 19.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prelude Therapeutics's current 3-Year FCF Growth Rate is 26.30%, which is 168% above median its own 10-year median of 9.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current 3-Year FCF Growth Rate of 26.30%. The current 3-Year FCF Growth Rate is 26.30%, which is 168% above median its 10-year median of 9.80 and 36.3% above the Biotechnology industry median of 19.30. Prelude Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current 3-Year FCF Growth Rate is 26.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
30GF Score
Get the complete analysis for PRLD
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRLD has been successfully added to your 
